2021-03-26 16:00Financial Performance - The company's operating revenue for 2020 was approximately CNY 1.33 billion, a decrease of 16.95% compared to 2019[12]. - The net profit attributable to shareholders for 2020 was approximately CNY 230 million, down 37.95% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was approximately CNY 206 million, a decrease of 42.25% compared to 2019[12]. - The basic earnings per share for 2020 was CNY 1.30, a decline of 42.73% from 2019[13]. - The company's total assets at the end of 2020 were approximately CNY 6.30 billion, an increase of 2.39% from the end of 2019[12]. - The company's net assets attributable to shareholders at the end of 2020 were approximately CNY 5.49 billion, an increase of 0.66% from the end of 2019[12]. - The company reported a quarterly revenue of CNY 440 million in Q4 2020, showing a positive trend in the latter half of the year[15]. - The company experienced a net loss of approximately CNY 25 million in Q1 2020, indicating challenges at the beginning of the year[15]. - The company achieved a total revenue of RMB 133,145.11 million in 2020, a decrease of RMB 27,087.37 million or 16.91% compared to the previous year[59]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in revenue from high-margin hyaluronic acid products[59]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - In 2020, the company distributed cash dividends of 7.00 RMB per 10 shares, totaling 124,044,620.00 RMB, which accounted for 33.46% of the net profit attributable to shareholders[155]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019[13]. - The R&D expenses for the reporting period amounted to CNY 126.47 million, an increase of CNY 10.40 million, representing a growth rate of 8.96%[42]. - The company has increased its R&D investment to enhance new technology and product development, focusing on collaboration with universities and research institutions[34]. - The company has established a comprehensive R&D system with 270 R&D personnel, accounting for 19.65% of total employees[119]. - The company is actively collaborating with domestic and international universities and research institutions to enhance its R&D capabilities and technology transfer[123]. Market Position and Product Lines - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. - The company is a leading domestic manufacturer of ophthalmic viscoelastic devices and intraocular lenses, with a complete product portfolio covering various materials and optical designs[19]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, with a complete range of hyaluronic acid injection products[23]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.64% in 2019, maintaining the top position for 13 consecutive years[32]. - The company holds a 45.85% market share in the domestic ophthalmic viscoelastic agent market and nearly 30% in the artificial lens market[64]. Compliance and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not violated decision-making procedures for external guarantees[3]. - There are no special arrangements for corporate governance[3]. - The company has committed to measures to compensate for any dilution of immediate returns since April 3, 2019, which is also valid for the long term[166]. Environmental Management - The company reported a total wastewater discharge of 76,092 tons and managed to keep all pollutant emissions within regulatory limits during the reporting period[198]. - The company processed 31.5259 tons of general waste and 44.6409 tons of hazardous waste, demonstrating its commitment to environmental management[198]. - The company has implemented effective waste treatment methods, ensuring compliance with environmental regulations for both wastewater and air emissions[199]. - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission terminal treatment facilities[200]. Strategic Initiatives - The company aims to enhance the quality of life for Chinese citizens and promote patient recovery, focusing on differentiated development in ophthalmology, aesthetic medicine, orthopedics, and surgery[149]. - The company is actively pursuing investment and acquisition opportunities in the global ophthalmic field to accelerate the localization of the Chinese ophthalmic industry[66]. - The company has established a strategic goal to become a leading domestic and internationally recognized biopharmaceutical enterprise in the field of biomedical materials[150]. - The company will integrate acquired businesses to maximize synergies and improve operational efficiency[151].